Addressing Nutritional Needs in Cancer

A recent phase 2 trial revealed that the combination of Tafinlar and Mekinist benefitted children with BRAF-mutated low-grade gliomas.

Cervical cancer survivor Kate Weissman talks recent research on follow-up visits for patients after fertility-sparing surgery, and explains why it’s ‘something that the cervical cancer community is owed.’

The Food and Drug Administration accepted an Investigational New Drug application for MB-109, a novel agent that combines two mechanisms to treat recurrent glioblastoma and high-grade astrocytroma.

Last week brought three more FDA approvals in the oncology space, as well as some research in neuropathy prevention and the diabetes-cancer connection.

As Len Goodman’s cause of death was announced and LSU defenseman Greg Brooks announces rare form of brain cancer, here is what’s happening in the oncology space this week.

The BRAF inhibitor AMB-1310 is currently being studied in both the United States and China for the treatment of patients with glioblastoma who are carrying the BRAF V600E mutation.